Cefuroxime axetil  is a semisynthetic, broad-spectrum cephalosporin antibiotic for oral administration. The in vivo bactericidal activity of cefuroxime axetil is due to its binding to essential target proteins and the resultant inhibition of cell-wall synthesis. Cefuroxime is bactericidal against a wide range of common pathogens, including many beta-lactamase–producing strains. It is stable to many bacterial beta-lactamases, especially plasmid-mediated enzymes that are commonly found in Enterobacteriaceae.

Pharyngitis/Tonsillitis, Acute Bacterial Otitis Media, Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), Acute Bacterial Maxillary Sinusitis. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis, Uncomplicated Skin and Skin-Structure Infections, Uncomplicated Urinary Tract Infections, Uncomplicated Gonorrhea, Early Lyme disease (erythema migrans).

•  Adolescents and Adults (13 years and older)
•  Pharyngitis/tonsillitis 250 mg b.i.d. 
•  Acute bacterial maxillary sinusitis 250 mg b.i.d. 
•  Acute bacterial exacerbations of chronic bronchitis 250 or 500 mg b.i.d. 
•  Secondary bacterial infections of acute bronchitis 250 or 500 mg b.i.d. 
•  Uncomplicated skin and skin-structure infections 250 or 500 mg b.i.d.
•  Uncomplicated urinary tract infections 250 mg b.i.d. 
•  Uncomplicated gonorrhea 1,000 mg once single dose
•  Early Lyme disease 500 mg b.i.d. 

 Patients with known hypersensitivity to cephalosporin antibiotics.

• Anaphylactic reaction to penicillin. Pseudomembranous colitis Over growth of non susceptible organisms.
• Paediatrics: Not safe in children below 3 months.
• Pregnancy: Use with caution.
• Lactation: Use with caution.

Skin rashes, Eosinophilia and transient increase of hepatic enzymes.

 Synergy with aminoglycosides.

4X10